Total 1Q 2023 revenue on FYARRO® sales of $5.9 million
PRECISION 1 tumor agnostic trial enrolling equally in TSC1 and TSC2 arms with more than 15 discreet tumor types represented
Read more at prnewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Total 1Q 2023 revenue on FYARRO® sales of $5.9 million
PRECISION 1 tumor agnostic trial enrolling equally in TSC1 and TSC2 arms with more than 15 discreet tumor types represented
Read more at prnewswire.com